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Abstract.  Transforming growth factor-13 (TGFI3)  is pro- 
duced by most cultured cells in an inactive form. 
Potential activation mechanisms of latent TGFI3 were 
studied using fibroblastic (NRK-49F and AKR-MCA) 
cell-conditioned medium as a  model. Active TGFI3 
was monitored by radioreceptor and soft agar assays as 
well as by antibody inhibition and immunoprecipita- 
tion.  Little or no TGF[3 was detected in untreated con- 
ditioned medium. Treatment of the medium with 
extremes of pH (1.5 or  12)  resulted in significant acti- 
vation of TGFI3 as shown by radioreceptor assays, 
while mild acid treatment (pH 4.5) yielded only 20- 
30%  of the competition achieved by pH  1.5. In an 
effort to define more physiological means of TGFI3 ac- 
tivation, the effects of some proteases were tested. 
Plasmin and cathepsin D  were found to generate 
25-kD bands corresponding to the active form of 
TGFI3 as shown by immunoprecipitation analysis of ra- 
diolabeled cell-conditioned medium. Plasmin treatment 
of the medium resulted in activity that was quantita- 
tively similar to that of mild acid treatment as mea- 
sured by radioreceptor and soft agar assays. In addi- 
tion, the plasmin-generated activity was inhibited by 
anti-TGFI3 antibodies.  Sequential treatments of AKR- 
MCA cell-conditioned medium with mild acid fol- 
lowed by plasmin or plasmin followed by mild acid 
gave activation comparable to either treatment alone. 
The data suggest that conditioned medium may contain 
at least two different pools of latent TGFI3. One pool is 
resistant to mild acid and/or plasmin and requires 
strong acid or alkali treatment for activation. A  second 
pool is activated by mild pH change and/or plasmin. 
Activation of this form of latent TGFI3 may take place 
by dissociation or proteolytic digestion from a  precur- 
sor molecule or hypothetical TGFl3-binding protein 
complex. 
T 
RANSFORMING growth factors (TGF) ~ are defined as 
proteins which stimulate the anchorage-independent 
growth of nontumorigenic cells (Todaro,  1982; Moses 
et al., 1981, Roberts et al., 1981). Two classes of TGF (TGFa 
and TGFI3) have been sequenced and molecularly character- 
ized.  TGFct  exhibits  sequence  homology  to  epidermal 
growth factor (Marquardt et al., 1984), binds to the epider- 
mal growth factor receptor, and is weakly mitogenic in soft 
agar. TGFI~, however, is structurally and functionally differ- 
ent from TGFa. TGF[3 is a highly ubiquitous protein and has 
been purified from several  normal tissues (Roberts et al., 
1982). Unlike TGFo, TGFI3 has its own specific cell surface 
receptors (Frolik et al., 1984; Tucker, et al., 1984; Massague 
and Like, 1985; Cheifetz et al., 1986; Cheifetz et al., 1987) 
and is a growth inhibitor for most cell types (Tucker et al., 
1984; Moses et al., 1985). The purified proteins elicit a vari- 
ety of biological effects in target cells (Moses et al.,  1985; 
Keski-Oja et al.,  1987). 
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Platelets, which contain large amounts of TGFI3, are the 
major source of TGFI3 found in normal serum (Childs et al., 
1982).  Purification by acid-ethanol extraction of platelets 
yields an intact active TGFI3 molecule with a molecular mass 
of 25 kD, which is comprised of two 12.5-kD chains linked 
by disulfide bonds (Assoian et al., 1983). The dimeric 25-kD 
form is biologically active while no activity can be detected 
after dissociation of the  chains  by  reducing  agents.  The 
TGFI3 present in human platelets has been termed TGFI31 
while two homodimeric forms (TGFI31 and TGFI32) and a 
heterodimeric form (TGFI31.2) have been observed in por- 
cine platelets. (Cheifetz et al., 1987). TGFI32 has been shown 
to be the same as the growth inhibitor isolated from BSC-1 
African green monkey kidney epithelial cells, now termed 
polyergin (Hanks et al.,  1988). 
While most cultured cells secrete TGFI3, it is usually in an 
inactive form (Lawrence et al., 1984). Extremes of pH have 
been shown to irreversibly activate TGF[3 in cell-conditioned 
media (Lawrence et al., 1985). Although acid activation has 
provided information regarding the production and secretion 
of TGFI3 from a variety of cell types, it is unlikely to be a 
physiological activation  mechanism.  Cell-associated  pro- 
teases were considered likely candidates in the activation 
since  proteolytic  processing  of  a  high  molecular  mass 
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eDNA sequencing studies (Derynck et al.,  1985). However, 
since the molecular character of inactive TGFI3 present in 
cell-conditioned medium (precursor or complex with a bind- 
ing protein) has not been elucidated, we use here the terms 
inactive or latent TGFI~. 
We find that a  fraction of inactive TGFI~ in cell-condi- 
tioned medium can be proteolytically activated by plasmin, 
a wide-spectrum serine protease. Our data suggest the exis- 
tence of two different inactive pools of this growth modulator 
secreted by cells in culture. The local activation of TGFIB in 
the vicinity of cells is expected to play an important role in 
the regulation of cellular growth, migration, and extracellu- 
lar matrix formation. Because TGFI~ can modulate the plas- 
minogen activator activity of cultured cells (Laiho et al., 
1986a, b), a physiological feedback mechanism for plasmin- 
mediated activation of latent TGFI3 is proposed. 
Materials and Methods 
Cell Culture and Collection of Conditioned Medium 
Continuous clonal cell  lines, AKR-MCA,  shown previously to produce 
TGFI3 (Moses et al.,  1981), and NRK-49F (DeLarco and Todaro,  1978), 
were used for the production of conditioned medium. The AKR-MCA cell 
line was obtained by transformation of parent AKR-2B cells with methyl- 
cholantrene (Getz et al., 1977; Moses et al., 1978). Stock cultures of AKR- 
MCA and NRK-49F (CRL-1570;  American Type Culture Collection, Rock- 
ville, MD) cells were maintained in McCoy's 5a medium supplemented with 
5% FBS (Gibco, Grand Island, NY) without antibiotics. For the production 
of conditioned medium, AKR-MCA cells were seeded in 490-cm  2 plastic 
roller bottles with 25 ml McCoy's 5a medium with 5 % FBS. NRK-49F cells 
were  seeded  in  75-cm  2 tissue  culture  flasks  with  15  ml  McCoy's  5a 
medium with 5% FBS. The medium was changed every 3-4 d until the cul- 
tures became confluent. Upon confluency, the cultures were rinsed three 
times with serum-free MCDB 402 medium and incubation was continued 
in fresh serum-free MCDB 402 medium. The medium was replaced every 
24 h and conditioned medium was collected from day 3 through day 7 of 
serum-free culture. The medium was centrifuged for 30 min in an RC-3B 
(Sorvall Instruments Div., part of DuPont Co., Wilmington, DE) at 4,000 
rpm to remove cell debris. Conditioned medium from each cell line was 
pooled separately, aliquoted, and stored at 4°C for subsequent activation 
studies. 
All TGFI3 activity assays were performed on AKR-2B (clone 84A) cells. 
Stock cultures of AKR-2B cells were maintained in McCoy's 5a medium 
supplemented with 5 % FBS. 
Treatment of Cell-conditioned Medium 
The pH of the conditioned medium was adjusted with HCI or NaOH and 
incubated at 22°C for 1 h  followed by neutralization with either HCI or 
NaOH  unless otherwise indicated.  Human  plasmin from two suppliers 
(Sigma Chemical Co., St. Louis, MO; Boehringer Mannheim Biochemi- 
cals, Indianapolis, IN) was used. Plasmin obtained from Sigma Chemical 
Co. was solubilized in PBS (0.14 M NaCI,  10 mM Na2HPO4, pH 7.4).  The 
conditioned medium was incubated with plasmin at concentrations  ranging 
from 0.01 to 3.0 U/ml. The incubations were performed at 37°C for 2 h. 
Protease activity was then inhibited by the addition of phenylmethylsulfonyl 
fluoride  (PMSF)  and  aprotinin  (final  concentrations:  2  mM  and  0.55 
TIU/ml, respectively). BSA (Sigma Chemical Co.) was subsequently added 
to a final  concentration of 1 mg/ml. Sequential treatments with acid and 
plasmin were performed as indicated. Immediately after the treatments, the 
conditioned medium was analyzed in the biological assays indicated. As a 
control, MCDB 402 medium not exposed to cells was incubated with plas- 
min (0.01-3.0 U/ml) in an identical manner to that described above for cell- 
conditioned medium.  Control  samples were  assayed  in parallel  experi- 
ments. 
Radioreceptor Assay 
AKR-2B cells were plated into 6-well culture dishes at a density of 2  ×  103 
cells/well in McCoy's 5a medium with 5% FBS. The following day, cells 
were washed three times with PBS and then incubated for 2 h at 22°C in 
the  presence of 0.25  ng  of  125I-labeled TGFI3 in  a  1-ml total  volume. 
Nonspecific binding was determined by the addition of 1 lag of 50%  pure 
unlabeled TGFI] (Tucker et al.,  1984) or by the addition of 10 ng/ml pure 
porcine TGFI3 (Research & Diagnostic Systems, Inc., Minneapolis, MN). 
AKR-MCA cell-conditioned medium was assayed for TGF~competing ac- 
tivity under neutral conditions, after acidification or alkalinization followed 
by neutralization,  and after plasmin treatments. Results of TGFI]  radio- 
receptor assays are represented as percent inhibition of binding after correc- 
tion for nonspecific binding. Nonspecific binding was <25%  of the total 
125I-TGFI~ bound. 
Sofl Agar  Assay 
Soft agar assays using AKR-2B cells were performed as previously de- 
scribed (Moses et al., 1981; Childs et al., 1982). Briefly, base layers of 0.8 % 
agar in McCoy's 5a medium supplemented with  10% FBS were prepared 
in 35-ram culture dishes. Upper layers of 0.4 % agar in McCoy's 5a medium 
contained 10%  FBS, 7.5  x  103 cells, and the conditioned medium after 
acid or  plasmin treatment as  indicated.  In parallel  experiments, AKR- 
MCA-conditioned medium after acid or plasmin treatment was incubated 
with anti-TGFl3 IgG or normal rabbit IgG overnight at 4°C before use in 
soft agar assays. The number of colonies >50 p.m that developed after 7-10 d 
was quantitated using an Omnicon Facs III image analyzer (Bausch & Lomb 
Inc., Rochester, NY). 
Immunoprecipitation of TGFlJ  from NRK-49F 
Cell-conditioned Medium 
Antibodies raised against  native TGFI3 were produced in  rabbits as de- 
scribed elsewhere (Keski-Oja et al., 1988b). Radiolabeling and immunopre- 
cipitation analyses were performed using NRK-49F cells. Confluent cul- 
tures were incubated with [35S]cysteine (50 p.Ci/ml, 1,000 I.tCi/mmol;  New 
England Nuclear, Boston, MA) in cysteine-free MEM for 48 h. The condi- 
tioned medium was treated with plasmin (0.4 U/ml) for 2 h at 22°C. Immu- 
noprecipitation was performed by incubation with 5 I.tg anti-TGF~ IgG or 
normal rabbit IgG for 4 h at room temperature or overnight at 4°C (Keski- 
Oja et al., 1987). Immune complexes were adsorbed with protein A-Sepha- 
rose and analyzed by SDS-PAGE followed by fluorography.  Radiolabeled 
molecular mass markers were purchased from Amersham Corp. (Arlington 
Heights, IL).  Reduced and nonreduced 1:5I-labeled TGFI3 was also sub- 
jected to electrophoresis as a specific mobility marker for TGF[3. 
Results 
Activation of TGF~ by Extremes of  pH 
AKR-MCA  cells  have  been  shown  previously  to  release 
TGFI3 into the medium (Moses et al.,  1981; Tucker et al., 
1983;  Moses et al.,  1987). However, the proportion of the 
TGFI3 in the active or latent form before acid treatment was 
not determined in the previous studies. This was examined 
by testing AKR-MCA and NRK-49F cell-conditioned medi- 
um in a TGFI~ radioreceptor assay. There was little if any ac- 
tive TGFI3 in untreated conditioned medium (Fig.  1). How- 
ever, repeated freezing and thawing  appeared to result in 
so'me degree of activation (Lyons, R. M., and H. L. Moses, 
unpublished data).  Therefore, untreated conditioned medi- 
um was used, extensively in this study as a control, usually 
without prior freezing. Acidification at pH  1.5 for 1 h  fol- 
lowed by neutralization resulted in the appearance of sig- 
nificant amounts of active TGFI3 in accordance with previous 
observations (Lawrence et al.,  1985;  Moses et al.,  1987). 
Similar  results  were  obtained  with  NRK-49F  cell-condi- 
tioned medium as suggested by the earlier results of Law- 
rence et al. (1984) in which soft agar assays were used. It has 
also been demonstrated that acid treatment of BSC-1 cell- 
conditioned medium results in the appearance of a  25-kD 
band which is specifically immunoprecipitated by anti-TGFI3 
antibodies (Keski-Oja et al.,  1987) verifying that the TGF[~- 
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Figure L  Acid activation of TGFI3 in NRK-49F and AKR-MCA 
cell-conditioned  medium.  The cell-conditioned  medium  (NRK- 
49F, ,,; AKR-MCA, m) was acidified to pH 1.5 for 1 h with HCI 
and  reneutralized with NaOH before use. Untreated cell-condi- 
tioned medium (NRK-49F, zx; AKR-MCA, n) was assayed at the 
same time. Increasing volumes of the medium were then assayed 
in triplicate for TFGI3-competing activity. 
competing activity generated by acid treatment is due to the 
production of active  TGFI3. The  two  cell  lines,  however, 
secreted different amounts of acid-activatable TGFI3 (Fig.  1). 
NRK-49F-conditioned medium contained 4 ng/ml and AKR- 
MCA-conditioned  medium  contained  2  ng/ml  with  50% 
inhibition  of  125I-TGFI3 binding,  representing  1  ng/ml  of 
TGFI3. 
An analysis of pH dependency for the activation of TGFI~ 
in AKR-MCA and NRK-49F cell-conditioned medium was 
performed (Fig. 2). It was found that both high and low pH 
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Figure 2.  Effect of pH on TGF[3 activation in cell-conditioned 
medium. Cell-conditioned medium (NRK-49F, A; AKR-MCA, =) 
was treated at the indicated pH by addition of HCI or NaOH and 
incubated at room temperature for 1 h. The medium was then neu- 
tralized and assayed in triplicate  (1  nil).  Data represent  specific 
binding after subtraction of background. 
Figure  3.  Immunoprecipitation  of 
TGFI3 from  NRK-49F  cell-condi- 
tioned medium.  Cell cultures  were 
incubated with [35S]cysteine  for 48 h 
and labeled conditioned medium was 
treated with plasmin as described in 
Materials  and  Methods. (Lane  1) 
Untreated medium precipitated with 
normal rabbit IgG; (lane 2) untreated 
medium precipitated with anti-TGFI3 
IgG; (lane 3) plasmin-treated medi- 
um precipitated with anti-TGFI3  IgG. 
The migration of radiolabeled pro- 
teins was visualized by autoradiogra- 
phy of a  10%  SDS-polyacrylamide 
gel. 
yielded nearly complete inhibition of t25I-TGFI3 binding.  A 
plateau  in  activation  occurred with  decreasing  pH  (4-5) 
resulting in 20-30%  inhibition of binding.  Physiologic pH 
(between 5.5 and 7.5) produced little or no TGFI3-competing 
activity in these assays. The results of these radioreceptor as- 
says confirmed previous reports that extremes of pH result 
in the activation of TGFI3 (Lawrence et al.,  1984; Lawrence 
et al., 1985; Pircher et al., 1986). To examine the possibility 
that the plateau in the pH curve between 4 and 5 represented 
activation of a pool of latent TGFI3 separate from that acti- 
vated at lower pH, a time course study of TGFI3 activation 
in AKR-MCA cell-conditioned medium at pH 4.75 was per- 
formed using receptor assays.  The degree of activation in- 
creased over 1.5 h  to 30%,  but little additional activation 
was produced with prolonged mild acid treatment (data not 
shown) further suggesting that the mild acid activatable pool 
may be a form of inactive TGFI3 distinct from that activated 
at lower pH. 
Activation of TGF[3 by Proteolysis 
Although mild acid or base treatment did generate TGFI3- 
competing activity, the biological significance of this finding 
is unclear. Proteolytic activation of a high molecular mass 
precursor, suggested from cDNA sequence data (Derynck et 
al.,  1986), was considered as a possible method for cellular 
processing of inactive TGFI3. Rabbit anti-TGFI3 antibodies 
were initially used to immunoprecipitate radiolabeled NRK- 
49F cell-conditioned medium treated with plasmin, cathep- 
sin  D,  elastase,  or  thrombin.  Both  plasmin  (Fig.  3)  and 
cathepsin D  (data not shown) treatment yielded a faint but 
specific 25-kD band which was sensitive to reduction with 
2-mercaptoethanol. No immunoreactive TGF~like polypep- 
tides were immunoprecipitated after treatment with elastase 
or  thrombin  (data  not  shown).  Plasmin  was  chosen  for 
further study  of TGFI3 activation in  immunoprecipitation 
analyses and biological assays because its effect in immuno- 
precipitation studies was most clear, and because of the wide 
distribution of plasminogen in vivo and the association of 
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Figure 4.  Plasmin activation of TGF~I. The cell-conditioned me- 
dium (NRK-49F, A; AKR-MCA, m) was incubated with the  in- 
dicated concentrations of plasmin at 37°C for 2 h. Protease activity 
was inhibited by PMSF and aprotinin (final concentrations of  2 mM 
and 0.55 TIU, respectively). BSA was added at a final concentration 
of 1 mg/ml. 1 ml of treated medium was assayed in triplicate for 
TGFI3 receptor-competing activity. MCDB 402 medium, not ex- 
posed to cells (zx), was treated with plasmin in an identical manner 
and assayed as a control. 
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Figure 5. (A) Soft agar assay of acid and plasmin activation of latent 
TGFI3. The conditioned medium was acid  (pH  1.5) or plasmin 
(0.2 U/ml) treated as  previously described  in  Materials  and 
Methods. Indicated volumes of treated and untreated medium were 
assayed in triplicate for the ability to stimulate the formation of 
colonies in soft agar. Variation between triplicate determinations 
was <10%. (B) Inhibition of plasmin-generated TGFI3 activity by 
anti-TGFI3 antibodies. AKR-MCA-conditioned  medium was treated 
with plasmin (0.2 U/ml) as described in Materials and Methods. 
After the addition of protease inhibitors, plasmin-treated condi- 
tioned medium was incubated with anti-TGFl~ antibodies at the in- 
dicated concentrations at 4°C overnight. The medium (500 lal) was 
then assayed for stimulation of soft agar colony formation. MCDB 
402 medium, not exposed to ceils, was treated identically and the 
number of colonies appearing under these conditions were sub- 
tracted as background. Data are represented as percent control: 
number of colonies formed by plasmin-treated conditioned medium 
in the absence of anti-TGFl3 antibodies. 
plasminogen activation with cell growth and transformation 
(Reich,  1980;  Dano et al.,  1985). 
A 62-kD band was also observed in immunopreciptation 
studies of NRK-49F cell-conditioned medium (Fig. 3). This 
polypeptide was present before and after acid treatment of 
cell-conditioned medium and was not sensitive to reduction 
with 2-mercaptoethanol.  In addition,  immunoprecipitation 
of this  polypeptide could not be  blocked by  the  addition 
of unlabeled TGFI~, suggesting nonspecific cross-reactivity 
with anti-TGFI3 antibodies (Keski-Oja et al.,  1988b). 
A dose-response study of AKR-MCA and NRK-49F cell- 
conditioned medium exposed to plasmin was carried out at 
37°C for 2 h. Increasing TGFI3-competing activity, as mea- 
sured by radioreceptor assay,  was obtained with increasing 
doses of  plasmin (Fig. 4). The maximum inhibition observed 
using AKR-MCA-conditioned medium was 20-30%, while 
50-60%  inhibition could be achieved with NRK-49F-con- 
ditioned medium. The lowest dose of plasmin that resulted 
in inhibition of binding was 0.1  U/ml.  Maximal inhibition 
was achieved with 0.5 U/ml with no additional inhibition at 
higher doses. The difference in the amount of maximal inhi- 
bition obtained by plasmin treatment of the different cell- 
conditioned media may be due to the difference in total se- 
creted inactive TGFI3 as suggested earlier (Fig.  1). Plasmin 
treatment of serum-free MCDB 402 medium not exposed to 
cells  did  not  create  any  competing activity  in  the  assay, 
demonstrating that plasmin itself did not interfere in the as- 
say  as  performed.  Treatment  of  ~25I-TGFfl with  plasmin 
concentrations used  here did  not appreciably degrade the 
protein or generate lower molecular mass fragments as deter- 
mined by autoradiography of ~25I-TGFI3 on SDS-polyacryl- 
amide gels (data not shown). This indicates that TGFfl is rel- 
atively resistant to digestion by plasmin. 
Plasmin  and  acid  activation  of AKR-MCA cell-condi- 
tioned medium were also compared in soft agar assays.  In- 
creasing amounts of acid-treated (pH 1.5) conditioned medi- 
um resulted in a dose-dependent increase in the number of 
colonies formed (Fig.  5 A).  A similar response to plasmin- 
treated  conditioned medium was observed, although fewer 
colonies  were  formed  at  each  concentration  of plasmin- 
treated  conditioned medium,  in accord with the results  of 
radioreceptor assays. 
As further immunologic characterization, we studied the 
effects of anti-TGFfl antibodies on plasmin-generated TGFI3- 
like activity in soft agar.  The antibodies inhibited  plasmin- 
generated soft agar growth of AKR-2B cells (Fig.  5 B) indi- 
cating that activation of a TFGI3-immunoreactive  protein was 
responsible  for  colony  formation.  Anti-TGFI3  antibodies 
were also able to inhibit colony formation associated with 
acid-treated AKR-MCA-conditioned medium in a dose-de- 
pendent manner (data not shown). These results suggest that 
plasmin is able to activate a fraction of the latent TGFI3 from 
conditioned  medium,  while  extremes  of  pH  will  yield 
greater activation. 
Sequential Effects of  pH and Plasmin 
To investigate  the possibility that the pool of latent TGFI3 in 
AKR-MCA cell-conditioned medium activated by mild acid 
was the same as that activated by plasmin, various combina- 
tions of pH and plasmin treatments were examined for their 
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Figure 6.  Sequential acid and/or plasmin treatment of AKR-MCA 
cell-conditioned medium. The indicated treatments of cell-condi- 
tioned medium were performed as described. The concentration of 
plasmin (0.3 U/ml) remained constant in these assays. Radiorecep- 
tor assays were performed on 1-ml aliquots of treated conditioned 
medium. Treated serum-free MCDB 402 medium was assayed and 
subtracted as background. Data represents the means of three inde- 
pendent experiments performed in triplicate with error bars indi- 
cating the standard deviation.  (*) One experiment performed in 
triplicate. 
possible additive effect in TGF~ activation (Fig.  6).  Mild 
acid (pH 4.5) or plasmin (0.3 U/ml) treatments of the condi- 
tioned medium alone resulted in 20-30% inhibition of ~25I- 
TGFI~ binding.  Mild acid followed by plasmin,  or plasmin 
followed by mild acid treatment, did not increase the inhi- 
bition  of  t2SI-TGFI3 binding.  Both  mild  acid  followed by 
strong acid and plasmin followed by strong acid produced 
TGFI3-competing activity comparable to strong acid alone. 
These results suggest that there may be two distinct forms of 
inactive TGFI~ in AKR-MCA cell-conditioned medium: an 
easily activatable pool which represents 20-30 % of total in- 
active TGFI~, and a second pool which requires extremes of 
pH or some unknown conditions for activation. 
Discussion 
A variety of cell types are known to secrete TGFI3 into the 
culture medium  in an  inactive form (Moses et al.,  1985; 
Keski-Oja et al.,  1987; Lawrence et al.,  1984).  In addition, 
most cells appear to have receptors for TGFI3 (Tucker et al., 
1984) indicating that activation of the latent form may be a 
major step in the regulation of TGFI3 action. Acidification of 
cell-conditioned  medium  is  frequently  used  to  monitor 
TGFI3 activity in either radioreceptor or soft agar assays. The 
physiological mechanisms of activation of the latent form(s) 
of TGFI3 are poorly understood.  In the present study, we 
demonstrate the ability of plasmin,  a  wide spectrum cell- 
associated serine protease, to activate a portion of the latent 
TGFI3 secreted by AKR-MCA mouse fibroblasts and NRK- 
49F rat fibroblasts. 
Acidification of cell-conditioned medium at pH  1.5 con- 
verts high molecular mass latent TGFI~ to lower molecular 
mass active material as measured by both radioreceptor and 
soft agar assays (Moses et al.,  1985; Lawrence et al.,  1984). 
To determine whether a change in pH might be a physiologi- 
cal means of activating latent TGFI3, a study of the effects of 
pH on measurable TGFI3 activity was performed. In accor- 
dance with the studies of Lawrence et al. (1985) on NRK-49F 
cells, we found that strong acid or base was capable of ac- 
tivating the maximum amount of the latent TGFI3 present in 
both NRK-49F and  AKR-MCA cell-conditioned medium• 
There was a twofold difference in the amount of acid-activat- 
able TGFI3 secreted by NRK-49F and AKR-MCA cells. Mild 
acid treatment (pH 4.5-5.5) of the conditioned medium re- 
sulted in only 20-30 % of the maximal activity obtained. The 
possibility that this range ofpH might be present in local mi- 
croenvironments at the cell surface or extracellular matrix of 
specific cell types under physiologic or pathologic circum- 
stances cannot be excluded. However, such a low pH is known 
to  exist  physiologically only  in  lysosomes  (Okhuma  and 
Poole, 1978). A lysosomal mechanism of activation of a poly- 
peptide  ligand  that  binds  to  cell  surface receptors seems 
unlikely. 
The  cell-associated  serine  protease,  plasmin,  was  also 
studied as a  potential biological activator of latent TGFI3. 
Plasmin was found to activate the same pool of latent TGFI3 
as that activated at pH 4.5. Such mild acid conditions would 
not be expected to cleave at the Arg-Arg site that must be 
cleaved for processing of the TGFI3 precursor (Derynck et 
al.,  1985).  Therefore, plasmin activation is probably medi- 
ated through cleavage at another site. Alternatively, the mild 
acid conditions could activate an acid protease present in the 
conditioned medium which in turn activates latent TGFI~ by 
precursor  cleavage.  We  favor  the  speculation  that  latent 
TGFI3 released into conditioned medium has already been 
proteolytically processed at the Arg-Arg site and that plas- 
min cleaves an associated polypeptide causing an irreversible 
conformational change which allows the release of the active 
25-kD TGFI3. The mild acid conditions could also result in 
denaturation of this proposed associated polypeptide. 
The high molecular mass of latent TGFI3 suggests the pres- 
ence of a binding protein (Lawrence et al.,  1985; Pircher et 
al.,  1986).  Previous  studies  have  shown  that  treatments 
known to dissociate hydrogen-bonded proteins activate latent 
TGFI3 (Lawrence et al.,  1985; Pircher et al.,  1986; Lyons, 
R.  M., and H.  L. Moses, unpublished data).  Whether the 
putative  binding  protein  is  the  non-TGFI3  portion  of the 
precursor molecule or the product of a separate gene is not 
known.  However,  recent  studies  by  Gentry  et  al.  (1987) 
would  suggest  that  TGFI~ remains  associated  with  the 
cleaved portion of its precursor molecule. These investiga- 
tors have transfected Chinese hamster ovary (CHO) cells 
with the full length TGFI3 gene and amplified the expression 
of TGFI~ by 500-fold. Conditioned medium from these trans- 
fected cells  required  acid  dialysis  for detection of active 
TGFI3, indicating that the overexpressing transfected CHO 
cells secrete TGFI3 in a latent form. If a separate gene was 
responsible  for providing  a  TGFI3-binding  protein,  coor- 
dinate overexpression of this gene would also be required to 
bind all secreted TGFfk A more plausible explanation would 
be  that  the  cleaved  25-kD  TGFfl  molecule  remains  as- 
sociated with the precursor portion of the molecule and thus 
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Figure 7.  Proposed model of 
TGFI~ activation by plasmin. 
Plasmin is activated from in- 
active  plasminogen by  PA. 
Plasmin may then proteolyti- 
cally activate inactive TGFI3  at 
or near the cell surface allow- 
ing its binding to the receptor. 
Binding of TGFI3 to the cells 
may then lead to production of 
the endothelial-type PA inhib- 
itor (Laiho et al., 1986a) which 
could  inhibit further  activa- 
tion of plasminogen resulting 
in a negative feedback of plas- 
min-mediated  TGFI3 activa- 
tion. 
TGFI~ remains inactive until dissociation occurs. Since acti- 
vation  is  irreversible,  there  is  probably  a  conformational 
change  of the  precursor portion upon dissociation of the 
complex such that the 25-kD active molecule can no longer 
bind to the precursor portion. The molecular nature of the 
putative  binding  protein  can  be  satisfactorily determined 
only  by  purification  and  sequencing.  The  pool  of latent 
TGFI3 in cell-conditioned medium requiring harsher condi- 
tions of acid or base which is not activated by plasmin treat- 
ment may require a more complex series of events clearly 
different from that required  for the  more easily activated 
pool. 
The possibility that plasmin may function as a physiologi- 
cal regulator of TGFI~ action by activation of latent material 
is strengthened by the observations that TGFI3 regulates ex- 
tracellular plasminogen  activator (PA)  activity. TGFI~ en- 
hances the production of the endothelial-type PA inhibitor 
(Laiho et al., 1986a) and decreases the mRNA levels and ex- 
tracellular activity of urokinase-type PA  in  cultured lung 
fibroblasts (Keski-Oja et al.,  1988a).  This could provide a 
negative feedback control of TGFI~ action (Fig. 7). The se- 
quence of events could be as follows. Cell-derived plasmino- 
gen activators convert plasminogen to plasmin which in turn 
activates  TGFI3  allowing  binding  to  specific  cell  surface 
receptors. Among other subsequent biological effects, TGFI~ 
increases the production of the endothelial-type PA inhibitor 
and decreases PA levels resulting in lower PA activity, less 
plasmin  production,  and  diminished  activation  of TGFfl. 
Proof of this or related mechanisms will require purification 
of the latent forms of TGFI3 as well as examination of cell 
membrane and extracellular matrix preparations for TGFI~- 
activating capability followed by purification of molecule(s) 
responsible for such activity. 
The possibility that local membrane or extracellular ma- 
trix components regulate  TGFI3 activity is  also  attractive 
from the standpoint that TGFI3 appears to be released in la- 
tent form by many cell types,  most of which  have TGFI~ 
receptors and are capable of responding in a variety of ways 
to active TGFI3. Therefore, proteolytic activation of latent 
TGFI~ at the cell surface or in the pericellular space could 
represent a major regulatory step in the action of this impor- 
tant regulatory molecule. 
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